The Bang For Celgene’s Buck: Looking Inside The Record-Setting Juno Deal

Celgene’s $1 billion collaboration with Juno was the highest ever upfront payment for a biopharma licensing deal. Execs broke down the deal specifics in an interview with “The Pink Sheet.”